CaSm/pancreatic cancer gene therapy (MUSC)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameCaSm/pancreatic cancer gene therapy (MUSC)
Drug Alias Namelocal adenoviral delivery (Medical University of South Carolina)p-GlcNAc local-regional adenoviral delivery system (MUSC)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionAntisense oligonucleotide inhibitors
TargetsUpdating
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMedical University Of South Carolina
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedical University Of South Carolina
Active IndicationsN/A
Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A